Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics announced additional positive results from two Phase 3 clinical trials, ACACIA-HCM and MAPLE-HCM, demonstrating that their drug aficamten improved cardiac function and symptoms in patients with non-obstructive and obstructive hypertrophic cardiomyopathy (HCM). Notably, ACACIA-HCM showed aficamten improved cardiac structure and diastoli…